This funding opportunity (FO) is expected to:

• Support partnerships between communities affected by HIV in Canada and researchers to facilitate the conduct of community-based research; and/or
• Develop future applications for more comprehensive community-based research grants.

Examples of activities that might be conducted under this request for applications are (but are not restricted to):

• Facilitation of dialogue between communities and researchers in order to establish research partnerships;
• Workshops to design a research project and/or develop a proposal for a future CBR operating grant;
• Planning and execution of pilot projects or feasibility studies to generate preliminary data, proof of concept; and/or
• Development and/or validation of new inventions, tools, methodologies, protocols, theoretical models or frameworks.

Background

In collaboration with Cancer Care Ontario, the Ontario Institute for Cancer Research (OICR) is excited to announce a new funding opportunity to support health services research projects that will provide the knowledge needed to optimize the delivery of cancer services today and to ensure appropriate dissemination of health service innovations and well-evaluated technologies.

Available funding

Up to $150,000 per year for a maximum of two years for projects related to one of the following priority areas. Projects that address hard-to-treat cancers and/or have a clear trajectory to intervention studies are preferred.

1. Data infrastructure, integration and mobilization studies (e.g., data linkage, quality, access, governance, and policy, including privacy and ethics considerations);
2. Use of Real-World Evidence to advance innovations in health care and health technology assessments;
3. Research addressing health care system adoption of accepted best practices related to precision medicine;
4. Use of artificial intelligence and digital health tools by health care systems and their impact on access to care, models of care, quality and cost of care, and patient outcomes;
5. Knowledge translation and dissemination projects; and
6. Population health studies (e.g., prevention and screening).

Eligibility

Investigators at Ontario academic institutions.

The Ontario Institute for Cancer Research (OICR) established the Cancer Therapeutics Innovation Pipeline (CTIP) strategic initiative to capitalize on Ontario’s expertise in cancer biology and drug discovery. CTIP aims to support the translation of Ontario discoveries into therapeutic assets with the potential for improving the lives of cancer patients.

To stimulate collaborative research with the Ontario cancer research community in the area of cancer therapeutics discovery, OICR invites applications for early stage drug discovery. This call for letters of intent (LOI) is for Early Accelerator projects.

Early Accelerator Projects

Focus on target identification/validation experiments and the generation of a validated primary assay to enable initial screening against a defined target.

Funding

Up to $100,000 per year for a maximum of one year.

The Canadian Hemophilia Society (CHS) is proud to put out its call for applications for its new research program created in collaboration with Bayer and ADVANCE Canada.

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.

The research program will support studies that aim to:

•             Identify and provide insight into key issues associated with the ageing hemophilia population

•             Identify how management of age-related co-morbidities should be adapted to those with hemophilia

•             Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia

The primary intent of this program is to offer one or two $30,000 research grants, to a maximum of $60,000 for one year.

All completed application forms and support documents must arrive at the National Office of the Canadian Hemophilia Society on or before August 31, 2018. If the CHS receives the application after the deadline date but it is postmarked on or before the deadline date, then it is considered to have been submitted on time. The names of the successful applicants will be announced by October, 2018.

Additional information, the eligibility criteria and conditions for the research program as well as the application form can be found on our website at this link:

https://www.hemophilia.ca/research-chs-bayer-advance-canada-research-program/

As outlined in Canada’s defence policy, Strong, Secure, Engaged, adapting and innovating quickly are crucial to developing and maintaining capabilities that address the challenges presented by today’s evolving global defence and security environment. To this end, innovation, knowledge, and problem solving are essential for Canada and its allies to mitigate threats and meet evolving defence and security needs.

In that context, the Innovation for Defence Excellence and Security (IDEaS) program will foster creativity and ingenuity in Canada by enabling the creation of networks of experts, providing support and opportunities to innovators, and by facilitating the integration and adoption of new capabilities for the defence and security communities.

Multi-institutional, multi-disciplinary teams, termed Micro-nets, are invited to submit research proposals on the following Innovation Challenge area from the defence and security community:

·        Autonomous Systems: Trust and Barriers to Adoption

The IDEaS Second Call for Proposals for Innovation Networks will provide non-repayable contribution funding to seed and sustain Micro-nets of at least five investigators from a minimum of three separate institutions or organizations from the academic, non-federal government, public and/or private sectors. A Canadian university must administer the contribution funds. Full details are available in the Innovation Networks Application Guide.

Micro-nets must propose interdisciplinary research programs aligned with the Innovation Challenge.

Funding will be provided by the IDEaS Transfer Payment Program, a federal government contribution program administered by the Department of National Defence.

The total budget for this call is $9,000,000.

Each Micro-net can request up to $1,500,000 over three years.

Co-funding is not mandatory, however participants from for-profit organizations will be required to contribute up to 50% of their costs.

Important dates:

Online portal for submission of Letters of Intent: opens July 16^th, 2018.

Deadline for submission of Letters of Intent: August 31^st , 2018, 12:00 pm (noon) EDT.

Deadline for submission of the Full Proposal: November 30^th, 2018, 12:00 pm (noon) EST.

An information session will be held in English on July 31^st, 2018. To register for this session please click on the link https://gts-ee.webex.com/gts-ee/onstage/g.php?MTID=e0abbbd4d9021dd4ade9bbd3d109c4d38 by July 26^th, 2018.

Please visit our website to learn how to register and apply for this call, and for more information about IDEaS. You may also contact us by email at IDEaS-IN.IDEeS-RI@forces.gc.ca.

FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

·         Prevent breast cancer (primary prevention)

·         Identify determinants of breast cancer initiation, risk, or susceptibility

·         Distinguish deadly from non-deadly breast cancers

·         Conquer the problems of over diagnosis and overtreatment

·         Identify what drives breast cancer growth; determine how to stop it

·         Identify why some breast cancers become metastatic

·         Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence

·         Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

·         Eliminate the mortality associated with metastatic breast cancer

Breakthrough Award Level 3 & 4– Preproposal due September 14, 2018

·         Independent investigators at all academic levels (or equivalent) are eligible to be names as PI.

·         Each investigator may submit one Funding Level 3 pre-application and on Funding Level 4 pre-application as a PI or Initiating PI.

·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         Potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.

·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.

·         When submitting the pre-application it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

·         Clinical trials are allowed.

·         There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·         Applications must include two or more breast cancer advocates on their research team.

·         Submission of a preproposal is required; application submission is by invitation only.

·         Funding Level 3:

·         Maximum funding of $2.5M in direct costs (plus indirect costs)

·         Maximum period of performance is 4 years

·         Funding Level 3 – Partnering PI Option:

·         Maximum funding of $4M for direct costs (plus indirect costs)

·         Maximum period of performance is 4 years

·         Funding Level 4 and Funding Level 4 – Partnering PI Option:

·         Maximum funding of $10M for direct costs (plus indirect costs)

·         Maximum period of performance is 4 years

FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

·         Prevent breast cancer (primary prevention)

·         Identify determinants of breast cancer initiation, risk, or susceptibility

·         Distinguish deadly from non-deadly breast cancers

·         Conquer the problems of over diagnosis and overtreatment

·         Identify what drives breast cancer growth; determine how to stop it

·         Identify why some breast cancers become metastatic

·         Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence

·         Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

·         Eliminate the mortality associated with metastatic breast cancer

http://cdmrp.army.mil/funding/bcrp

Breakthrough Award Level 1 & 2– Letter of Intent due November 1, 2018

·         Investigators at all academic levels (or equivalent) are eligible to be names as Principal Investigator (PI).

·         Applications from senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged underfunding Level 1 and 2.

·         Each investigator may be named on only one Funding Level 1 application and Funding Level 2 application as a PI or Initiating PI.

·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.

·         When submitting the pre-application, it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

·         There are no limitations on the number of applications for which an investigator may be named as a

·         Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·         Additional funds are available for applications submitted under the Partnering PI Option.

·         Clinical trials are not allowed.

·         Submission of a Letter of Intent is required prior to full application submission.

·         Funding Level 1:

·         Maximum funding of $375,000 for direct costs (plus indirect costs)

·         Maximum period of performance is 3 years

·         Funding Level 1 – Partnering PI Option:

·         Maximum funding of $600,000 for direct costs (plus indirect costs)

·         Maximum period of performance is 3 years

·         Funding Level 2:

·         Maximum funding of $750,000 for direct costs (plus indirect costs)

·         Maximum period of performance is 3 years

·         Funding Level 2 – Partnering PI Option:

·         Maximum funding of $1M for direct costs (plus indirect costs)

·         Maximum period of performance is 3 years

The Canadian Foundation for Healthcare Improvement (CFHI) is launching a new, 17-month spread collaborative to
improve the quality of care and patient and caregiver1 experiences of care during transitions from hospital to home. Using
a quality improvement (QI) approach, improvement teams – comprised of patient and caregiver advisors, providers and
leaders from hospitals, home and community organizations – will implement a patient-oriented care transitions bundle
that focuses on what patients and caregivers want and need to increase their confidence for a safe transition from hospital
to home. This bundle includes:
• a patient-oriented discharge summary (PODS)
• patient and caregiver education using effective methods such as teach-back
• the involvement of caregivers (where possible) as part of the circle of care at key points throughout a hospital stay
• post-discharge follow-up

Accepted teams are eligible for up to $40,000 in seed funding, coaching, and numerous learning and networking
opportunities to support the design, implementation and evaluation of this initiative.

The goals of the spread collaborative are to:
• Improve the patient and caregiver experience of transitions from hospital to home/community care
• Improve the confidence of patients (and caregivers) to manage their care as they transition to home
• Improve provider experience of care
• Reduce avoidable hospital readmissions
• Enhance the ability of teams to effectively partner with patients and caregivers in improvement initiatives

This collaborative will advance the shared priority of enhancing home and community care by spreading evidence-based
innovations that provide patients and caregivers with the knowledge and confidence they need to manage their care
at home or in the community.

The deadline to apply is August 15, 2018.

BWF's Career Awards at the Scientific Interface (CASI) provide $500,000 over five years to bridge advanced postdoctoral training and the first three years of faculty service. These awards are open to U.S. and Canadian citizens, permanent residents, and temporary residents.

Details

These grants are intended to foster the early career development of researchers who have transitioned or are transitioning from undergraduate and/or graduate work in the physical/mathematical/computational sciences or engineering into postdoctoral work in the biological sciences, and who are dedicated to pursuing a career in academic research.

Scientific advances such as genomics, quantitative structural biology, imaging techniques, and modeling of complex systems have created opportunities for exciting research careers at the interface between the physical/computational sciences and the biological sciences. Tackling key problems in biology will require scientists trained in areas such as chemistry, physics, applied mathematics, computer science, and engineering.

The objective of the Idea to Innovation (I2I) Grants  is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established Canadian company. The I2I Grants provide funding to college and university faculty members to support research and development projects with recognized technology transfer potential. This is achieved through defined phases by providing crucial assistance in the early stages of technology validation and market connection.